Thank you for your informative post. My point was ONLY related to the nill effect on TRCA share price; not on the data. Purely from a business perspective: they blew it, IMHO. They had first blood with FDA approval and share price has dropped from over $12 to the $3's. I say, apparently, the medical community is not anxious to embrace their product. TO ME, the company sounds desperate to stop the bleeding pps, and all I meant was, today's PR did not help much.
Best to you!
Market Data 
Markets 
AI
